-
1
-
-
84874533863
-
Nephropathy in diabetes
-
B. Satirapoj, "Nephropathy in diabetes," Advances in Experimental Medicine and Biology, vol. 771, no. 1, pp. 107-122, 2012.
-
(2012)
Advances in Experimental Medicine and Biology
, vol.771
, Issue.1
, pp. 107-122
-
-
Satirapoj, B.1
-
2
-
-
84869492851
-
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
-
H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al., "Cardiorenal end points in a trial of aliskiren for type 2 diabetes," The New England Journal ofMedicine, vol. 367, no. 23, pp. 2204-2213, 2012.
-
(2012)
The New England Journal OfMedicine
, vol.367
, Issue.23
, pp. 2204-2213
-
-
Parving, H.-H.1
Brenner, B.M.2
McMurray, J.J.V.3
-
3
-
-
84890946148
-
Bardoxolonemethyl in type 2 diabetes and stage 4 chronic kidney disease
-
D. de Zeeuw, T. Akizawa, P. Audhya et al., "Bardoxolonemethyl in type 2 diabetes and stage 4 chronic kidney disease," The New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503, 2013.
-
(2013)
The New England Journal of Medicine
, vol.369
, Issue.26
, pp. 2492-2503
-
-
De Zeeuw, D.1
Akizawa, T.2
Audhya, P.3
-
4
-
-
10744223527
-
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
-
W. K. Bolton, D. C. Cattran, M. E. Williams et al., "Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy," The American Journal of Nephrology, vol. 24, no. 1, pp. 32-40, 2004.
-
(2004)
The American Journal of Nephrology
, vol.24
, Issue.1
, pp. 32-40
-
-
Bolton, W.K.1
Cattran, D.C.2
Williams, M.E.3
-
5
-
-
79957467422
-
Review on pathophysiology and treatment of diabetic kidney disease
-
B. Satirapoj, "Review on pathophysiology and treatment of diabetic kidney disease," Journal of the Medical Association of Thailand, vol. 93, supplement 6, pp. S228-S241, 2010.
-
(2010)
Journal of the Medical Association of Thailand
, vol.93
, pp. S228-S241
-
-
Satirapoj, B.1
-
6
-
-
40449113524
-
The role of inflammatory cytokines in diabetic nephropathy
-
J. F. Navarro-González and C. Mora-Fernández, "The role of inflammatory cytokines in diabetic nephropathy," Journal of the American Society ofNephrology, vol. 19,no. 3, pp. 433-442, 2008.
-
(2008)
Journal of the American Society OfNephrology
, vol.19
, Issue.3
, pp. 433-442
-
-
Navarro-González, J.F.1
Mora-Fernández, C.2
-
7
-
-
0029355274
-
Fibrosis linked to TGF-beta in yet another disease
-
W. A. Border and N. A. Noble, "Fibrosis linked to TGF-beta in yet another disease,"The Journal of Clinical Investigation, vol. 96, no. 2, pp. 655-656, 1995.
-
(1995)
The Journal of Clinical Investigation
, vol.96
, Issue.2
, pp. 655-656
-
-
Border, W.A.1
Noble, N.A.2
-
8
-
-
0025277164
-
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1
-
W. A. Border, S. Okuda, L. R. Languino, M. B. Sporn, and E. Ruoslahti, "Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1," Nature, vol. 346, no. 6282, pp. 371-374, 1990.
-
(1990)
Nature
, vol.346
, Issue.6282
, pp. 371-374
-
-
Border, W.A.1
Okuda, S.2
Languino, L.R.3
Sporn, M.B.4
Ruoslahti, E.5
-
9
-
-
0029905441
-
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
-
Y. Isaka, D. K. Brees, K. Ikegaya et al., "Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney," Nature Medicine, vol. 2, no. 4, pp. 418-423, 1996.
-
(1996)
Nature Medicine
, vol.2
, Issue.4
, pp. 418-423
-
-
Isaka, Y.1
Brees, D.K.2
Ikegaya, K.3
-
10
-
-
0029924637
-
Neutralization of TGF-by anti-TGF-antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZinduced diabetic mice
-
K. Sharma, Y. Jin, J. Guo, and F. N. Ziyadeh, "Neutralization of TGF-by anti-TGF-antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZinduced diabetic mice," Diabetes, vol. 45, no. 4, pp. 522-530, 1996.
-
(1996)
Diabetes
, vol.45
, Issue.4
, pp. 522-530
-
-
Sharma, K.1
Jin, Y.2
Guo, J.3
Ziyadeh, F.N.4
-
11
-
-
0036014944
-
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di. N. A. S. Randomized trial
-
G. Gambaro, I. Kinalska, A. Oksa et al., "Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. N. A. S. randomized trial," Journal of theAmerican Society of Nephrology, vol. 13, no. 6, pp. 1615-1625, 2002.
-
(2002)
Journal of TheAmerican Society of Nephrology
, vol.13
, Issue.6
, pp. 1615-1625
-
-
Gambaro, G.1
Kinalska, I.2
Oksa, A.3
-
12
-
-
0030071492
-
Effect of suiphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy
-
J. T. Tamsma, F. J. vanderWoude, andH. H. P. J. Lemkes, "Effect of suiphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy," Nephrology Dialysis Transplantation, vol. 11, no. 1, pp. 182-185, 1996.
-
(1996)
Nephrology Dialysis Transplantation
, vol.11
, Issue.1
, pp. 182-185
-
-
Tamsma, J.T.1
Vanderwoude, F.J.2
Lemkes, H.H.P.J.3
-
13
-
-
0028092966
-
Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy
-
G. Gambaro, A. P. Venturini, D. M. Noonan et al., "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy," Kidney International, vol. 46, no. 3, pp. 797-806, 1994.
-
(1994)
Kidney International
, vol.46
, Issue.3
, pp. 797-806
-
-
Gambaro, G.1
Venturini, A.P.2
Noonan, D.M.3
-
14
-
-
0026659040
-
Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats
-
G. Gambaro, A. O. Cavazzana, P. Luzi et al., "Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats," Kidney International, vol. 42, no. 2, pp. 285-291, 1992.
-
(1992)
Kidney International
, vol.42
, Issue.2
, pp. 285-291
-
-
Gambaro, G.1
Cavazzana, A.O.2
Luzi, P.3
-
15
-
-
0033672331
-
Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-termdiabetic rats
-
M. Ceol, G. Gambaro, U. Sauer et al., "Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-termdiabetic rats," Journal of the American Society of Nephrology, vol. 11, no. 12, pp. 2324-2336, 2000.
-
(2000)
Journal of the American Society of Nephrology
, vol.11
, Issue.12
, pp. 2324-2336
-
-
Ceol, M.1
Gambaro, G.2
Sauer, U.3
-
16
-
-
84903135790
-
Heparanase is a key player in renal fibrosis by regulating TGF-expression and activity
-
V. Masola, G. Zaza, M. F. Secchi, G. Gambaro, A. Lupo, and M. Onisto, "Heparanase is a key player in renal fibrosis by regulating TGF-expression and activity," Biochimica et Biophysica Acta, vol. 1843, no. 9, pp. 2122-2128, 2014.
-
(2014)
Biochimica et Biophysica Acta
, vol.1843
, Issue.9
, pp. 2122-2128
-
-
Masola, V.1
Zaza, G.2
Secchi, M.F.3
Gambaro, G.4
Lupo, A.5
Onisto, M.6
-
17
-
-
0033661906
-
Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c
-
C. Ito, R. Maeda, S. Ishida, H. Sasaki, and H. Harada, "Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c," Diabetes Research and Clinical Practice, vol. 50, no. 3, pp. 225-230, 2000.
-
(2000)
Diabetes Research and Clinical Practice
, vol.50
, Issue.3
, pp. 225-230
-
-
Ito, C.1
Maeda, R.2
Ishida, S.3
Sasaki, H.4
Harada, H.5
-
18
-
-
33847202536
-
Improvement of renal function in type 2 diabetic nephropathy
-
N. Futrakul, P. Butthep, P. Futrakul, and V. Sitprija, "Improvement of renal function in type 2 diabetic nephropathy," Renal Failure, vol. 29, no. 2, pp. 155-158, 2007.
-
(2007)
Renal Failure
, vol.29
, Issue.2
, pp. 155-158
-
-
Futrakul, N.1
Butthep, P.2
Futrakul, P.3
Sitprija, V.4
-
19
-
-
0027479442
-
Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy
-
T. Yamamoto, T. Nakamura, N. A. Noble, E. Ruoslahti, and W. A. Border, "Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 5, pp. 1814-1818, 1993.
-
(1993)
Proceedings of the National Academy of Sciences of the United States of America
, vol.90
, Issue.5
, pp. 1814-1818
-
-
Yamamoto, T.1
Nakamura, T.2
Noble, N.A.3
Ruoslahti, E.4
Border, W.A.5
-
20
-
-
84858765166
-
Novel insights into the relationship between glomerular pathology and progressive kidney disease
-
B. Satirapoj, C. C. Nast, and S. G. Adler, "Novel insights into the relationship between glomerular pathology and progressive kidney disease," Advances in Chronic Kidney Disease, vol. 19, no. 2, pp. 93-100, 2012.
-
(2012)
Advances in Chronic Kidney Disease
, vol.19
, Issue.2
, pp. 93-100
-
-
Satirapoj, B.1
Nast, C.C.2
Adler, S.G.3
-
21
-
-
0029060919
-
Overexpression of transforming growth factor-1 mRNA is associated with upregulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice
-
C.-W. Yang, M. Hattori, H. Vlassara et al., "Overexpression of transforming growth factor-1 mRNA is associated with upregulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice," Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1610-1617, 1995.
-
(1995)
Journal of the American Society of Nephrology
, vol.5
, Issue.8
, pp. 1610-1617
-
-
Yang, C.-W.1
Hattori, M.2
Vlassara, H.3
-
22
-
-
0031053824
-
Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes
-
I. S. Park, H. Kiyomoto, S. L. Abboud, and H. E. Abboud, "Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes," Diabetes, vol. 46, no. 3, pp. 473-480, 1997.
-
(1997)
Diabetes
, vol.46
, Issue.3
, pp. 473-480
-
-
Park, I.S.1
Kiyomoto, H.2
Abboud, S.L.3
Abboud, H.E.4
-
23
-
-
0029924863
-
High glucose-induced TGF-1 regulates mesangial production of heparan sulfate proteoglycan
-
V. Kolm, U. Sauer, B. Olgemöller, and E. D. Schleicher, "High glucose-induced TGF-1 regulates mesangial production of heparan sulfate proteoglycan," The American Journal of Physiology, vol. 270, no. 5, part 2, pp. F812-F821, 1996.
-
(1996)
The American Journal of Physiology
, vol.270
, Issue.5
, pp. F812-F821
-
-
Kolm, V.1
Sauer, U.2
Olgemöller, B.3
Schleicher, E.D.4
-
24
-
-
0030957881
-
Glycosaminoglycans delay the progression of nephropathy in NIDDM
-
A. Solini, L. Vergnani, F. Ricci, and G. Crepaldi, "Glycosaminoglycans delay the progression of nephropathy in NIDDM," Diabetes Care, vol. 20, no. 5, pp. 819-823, 1997.
-
(1997)
Diabetes Care
, vol.20
, Issue.5
, pp. 819-823
-
-
Solini, A.1
Vergnani, L.2
Ricci, F.3
Crepaldi, G.4
-
25
-
-
0342327339
-
Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients
-
J. ?Skrha, J. Peru?si?cová, P. Pont'Uch, and A. Ok?sa, "Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients," Diabetes Research and Clinical Practice, vol. 38, no. 1, pp. 25-31, 1997.
-
(1997)
Diabetes Research and Clinical Practice
, vol.38
, Issue.1
, pp. 25-31
-
-
Skrha, J.1
Perusicová, J.2
Pont'Uch, P.3
Oksa, A.4
-
26
-
-
77955440687
-
Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy
-
S. Blouza, S. Dakhli, H. Abid et al., "Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy," Journal of Nephrology, vol. 23, no. 4, pp. 415-424, 2010.
-
(2010)
Journal of Nephrology
, vol.23
, Issue.4
, pp. 415-424
-
-
Blouza, S.1
Dakhli, S.2
Abid, H.3
-
27
-
-
33846443180
-
Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients
-
B. Sulikowska, H. Olejniczak, M. Muszýnska et al., "Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients," American Journal of Nephrology, vol. 26, no. 6, pp. 621-628, 2006.
-
(2006)
American Journal of Nephrology
, vol.26
, Issue.6
, pp. 621-628
-
-
Sulikowska, B.1
Olejniczak, H.2
Muszýnska, M.3
-
28
-
-
80055018022
-
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: A randomized controlled trial
-
E. J. Lewis, J. B. Lewis, T. Greene et al., "Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial," American Journal of Kidney Diseases, vol. 58, no. 5, pp. 729-736, 2011.
-
(2011)
American Journal of Kidney Diseases
, vol.58
, Issue.5
, pp. 729-736
-
-
Lewis, E.J.1
Lewis, J.B.2
Greene, T.3
-
29
-
-
84863393468
-
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy
-
D. K. Packham, R. Wolfe, A. T. Reutens et al., "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy," Journal of theAmericanSociety ofNephrology, vol. 23, no. 1, pp. 123-130, 2012.
-
(2012)
Journal of TheAmericanSociety OfNephrology
, vol.23
, Issue.1
, pp. 123-130
-
-
Packham, D.K.1
Wolfe, R.2
Reutens, A.T.3
-
30
-
-
77953013434
-
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy
-
M. Rossini, T. Naito, H. Yang et al., "Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy," Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1803-1810, 2010.
-
(2010)
Nephrology Dialysis Transplantation
, vol.25
, Issue.6
, pp. 1803-1810
-
-
Rossini, M.1
Naito, T.2
Yang, H.3
-
31
-
-
84878568490
-
Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats
-
J. J. Cha, Y. S. Kang, Y. Y. Hyun et al., "Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats," Life Sciences, vol. 92, no. 23, pp. 1118-1124, 2013.
-
(2013)
Life Sciences
, vol.92
, Issue.23
, pp. 1118-1124
-
-
Cha, J.J.1
Kang, Y.S.2
Hyun, Y.Y.3
|